FHTX
NASDAQ · Biotechnology
Foghorn Therapeutics Inc
$4.61
+0.08 (+1.77%)
Financial Highlights (FY 2026)
Revenue
37.94M
Net Income
-91,185,717
Gross Margin
—
Profit Margin
-240.3%
Rev Growth
+17.1%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 35.6% | 35.6% |
| Operating Margin | -279.5% | -251.5% | 5.1% | 4.9% |
| Profit Margin | -240.3% | -228.3% | 4.9% | 5.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 37.94M | 32.39M | 271.86M | 230.16M |
| Gross Profit | — | — | 96.87M | 82.01M |
| Operating Income | -106,047,318 | -81,477,365 | 13.80M | 11.27M |
| Net Income | -91,185,717 | -70,059,027 | 13.33M | 11.49M |
| Gross Margin | — | — | 35.6% | 35.6% |
| Operating Margin | -279.5% | -251.5% | 5.1% | 4.9% |
| Profit Margin | -240.3% | -228.3% | 4.9% | 5.0% |
| Rev Growth | +17.1% | +17.1% | -6.6% | +8.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 139.92M | 178.86M |
| Total Equity | — | — | 241.00M | 245.51M |
| D/E Ratio | — | — | 0.58 | 0.73 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -101,954,831 | -82,684,897 | 20.13M | 16.16M |
| Free Cash Flow | — | — | 11.27M | 12.60M |